Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 11/20 | 0.82 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.70 |
| ▸ | SCN1A | P35498 | 2/20 | 0.70 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.70 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.70 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.70 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160379 | 0.93 | SCN3A (0.80) | SCN3ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL3125226 | 0.90 | SCN3A (1.00) | SCN3ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL3161008 | 0.90 | SCN3A (0.86) | SCN3ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL3160028 | 0.90 | SCN3A (0.67) | SCN3ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL3165510 | 0.89 | SCN3A (0.69) | SCN3ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL3173728 | 0.88 | SCN3A (0.82) | SCN3ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL3159795 | 0.86 | SCN3A (0.76) | SCN3ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL3171623 | 0.86 | SCN3A (1.00) | SCN3ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL3167795 | 0.86 | SCN3A (0.70) | SCN3ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL3168326 | 0.85 | SCN3A (0.80) | SCN3ASCN9ASCN1ASCN5ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | SCN3A 13/4885SCN9A 51/4885SCN1A 6/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | SCN3A 13/4885SCN9A 51/4885SCN1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.